ARTICLE | Company News
FDA approves AZ's hairy cell leukemia drug
September 13, 2018 9:02 PM UTC
FDA approved Lumoxiti moxetumomab pasudotox-tdfk from AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat relapsed or refractory hairy cell leukemia in adults who have received at least two prior systemic therapies, including a purine nucleoside analog.
Lumoxiti, an anti-CD22 antibody variable fragment fused to the PE38 immunotoxin, has Orphan Drug status from FDA...
BCIQ Company Profiles
BCIQ Target Profiles